Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone + droperidol
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of dexamethasone (a corticosteroid) and droperidol (a butyrophenone derivative and dopamine antagonist) used primarily for the prevention and treatment of postoperative nausea and vomiting (PONV). Dexamethasone relieves inflammation while droperidol produces tranquilization and reduces nausea/vomiting by acting as a dopamine antagonist. The combination has an additive antiemetic effect, particularly when combined with ondansetron.
02
Targets
GR (Glucocorticoid receptor)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on dexamethasone + droperidol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexamethasone + droperidol.